WELCOME TO The Biotechnology REPORT
Genetics & IVF Institute, Inc.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Integrated DNA Technologies | February 15, 2016
Sophia Genetics, the global leader in Data-Driven Medicine (DDM), announced today the signing of a new strategic partnership with Integrated DNA Technologies (IDT). Under the terms of the agreement, Sophia Genetics will combine its Sophia DDM™ analytics platform with IDT’s NGS target capture products. The new bundle will create the most advanced NGS data analytics platform in the market. With these bundle solutions, Sophia Genetics will address the needs of European hospitals t...
Seattle Genetics | February 09, 2017
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and year 2016 financial results on Thursday, February 9, after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update...
Seattle Genetics | January 05, 2017
Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company, today announced enrollment of the first patient in a multicenter phase 1 clinical trial of SGN-CD352A for patients with relapsed or refractory multiple myeloma (MM). SGN-CD352A is an investigational CD352-targeted antibody-drug conjugate (ADC) utilizing Seattle Genetics’ proprietary ADC technology, an engineered cysteine antibody (EC-mAb) stably linked to a highly potent cytotoxic agent called a pyrrolobenzodiazepine (P...
Seattle Genetics | December 27, 2016
Seattle Genetics, Inc. (Nasdaq:SGEN), a global biotechnology company, today announced that it has received notice from the U.S. Food and Drug Administration (FDA) that a clinical hold or partial clinical hold has been placed on several early stage trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia (AML)...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE